Cargando…

CAR‐T cell therapy for lung cancer: Potential and perspective

Lung cancer is the highest incidence and mortality of all cancers around the world. In the present immunotherapy era, an increasing number of immunotherapeutic agents including monoclonal antibody‐targeted drugs have been used in the clinical treatment of malignancy, but it still has many limitation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Long, Chen, Fukun, Li, Jindan, Pu, Yongzhu, Yang, Conghui, Wang, Yue, Lei, Yujie, Huang, Yunchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977151/ https://www.ncbi.nlm.nih.gov/pubmed/35289077 http://dx.doi.org/10.1111/1759-7714.14375

Ejemplares similares

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century
por: Huang, Rong, et al.
Publicado: (2022)

The value of AI in the Diagnosis, Treatment, and Prognosis of Malignant Lung Cancer
por: Wang, Yue, et al.
Publicado: (2022)

The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions
por: Li, Jindan, et al.
Publicado: (2023)

The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence
por: Jiang, Jie, et al.
Publicado: (2022)

Role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and treatment response assessment of primary bone lymphoma
por: Pu, Yongzhu, et al.
Publicado: (2023)

The clinical application of (18)F-FDG PET/CT in pancreatic cancer: a narrative review
por: Pu, Yongzhu, et al.
Publicado: (2021)

A multi‐omics perspective of CAR T cell therapy
por: Yang, Jingwen, et al.
Publicado: (2023)

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives
por: Maher, John
Publicado: (2023)

Tree shrew as a new animal model for the study of lung cancer
por: YE, LIANHUA, et al.
Publicado: (2016)

The Potential of CAR T Cell Therapy in Pancreatic Cancer
por: Akce, Mehmet, et al.
Publicado: (2018)

CAR-T cell therapy for lung cancer: a promising but challenging future
por: Zhong, Shupeng, et al.
Publicado: (2020)

Benign pancreatic lesion on (18)F-FDG PET-MRI: A case report
por: Xiao, Yuqiang, et al.
Publicado: (2023)

Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells
por: Fujiwara, Hiroshi
Publicado: (2021)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
por: Qu, Jingjing, et al.
Publicado: (2020)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges
por: Hu, Qiuyuan, et al.
Publicado: (2023)

Lung cancer family history and exposure to occupational/domestic coal combustion contribute to variations in clinicopathologic features and gene fusion patterns in non‐small cell lung cancer
por: Chen, Ying, et al.
Publicado: (2019)

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
por: Ma, Hong Yun, et al.
Publicado: (2023)

囊腔型肺癌的诊疗进展
por: YANG, Jinxu, et al.
Publicado: (2023)

The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer
por: Chen, Yangming, et al.
Publicado: (2020)

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers
por: Yang, Yanlong, et al.
Publicado: (2017)

Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy
por: Tang, Xiang-Jun, et al.
Publicado: (2015)

Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
por: Hu, Chunmei, et al.
Publicado: (2023)

CAR-T Cells for the Treatment of Lung Cancer
por: Chocarro, Luisa, et al.
Publicado: (2022)

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
por: Jogalekar, Manasi P., et al.
Publicado: (2022)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

CAR-T Cells: Future Perspectives
por: Charrot, Sarah, et al.
Publicado: (2019)

Mxi1 participates in the progression of lung cancer via the microRNA-300/KLF9/GADD34 Axis
por: Lei, Yujie, et al.
Publicado: (2022)

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
por: Kandra, Prameela, et al.
Publicado: (2022)

Recent advances in CAR-T cells therapy for colorectal cancer
por: Qin, Xiaoling, et al.
Publicado: (2022)

miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathway in vivo and vitro
por: Wei, Xueqiang, et al.
Publicado: (2020)

CAR-T cell therapy: current limitations and potential strategies
por: Sterner, Robert C., et al.
Publicado: (2021)

CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
por: Thomas, Pauline, et al.
Publicado: (2021)

Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer
por: Yang, Yeqing Angela, et al.
Publicado: (2015)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models
por: Qin, Diyuan, et al.
Publicado: (2020)

Current progress in CAR-T cell therapy for tumor treatment
por: Chen, Lei, et al.
Publicado: (2022)

Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges
por: Chen, Fukun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vc3l3dqfn88i86sjr6g29gcbd6